Hidalgo-Tenorio, C.; Pasquau, J.; Vinuesa, D.; Ferra, S.; Terrón, A.; SanJoaquín, I.; Payeras, A.; Martínez, O.J.; López-Ruz, M.Á.; Omar, M.;
et al. DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks). Viruses 2022, 14, 524.
https://doi.org/10.3390/v14030524
AMA Style
Hidalgo-Tenorio C, Pasquau J, Vinuesa D, Ferra S, Terrón A, SanJoaquín I, Payeras A, Martínez OJ, López-Ruz MÁ, Omar M,
et al. DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks). Viruses. 2022; 14(3):524.
https://doi.org/10.3390/v14030524
Chicago/Turabian Style
Hidalgo-Tenorio, Carmen, Juan Pasquau, David Vinuesa, Sergio Ferra, Alberto Terrón, Isabel SanJoaquín, Antoni Payeras, Onofre Juan Martínez, Miguel Ángel López-Ruz, Mohamed Omar,
and et al. 2022. "DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)" Viruses 14, no. 3: 524.
https://doi.org/10.3390/v14030524
APA Style
Hidalgo-Tenorio, C., Pasquau, J., Vinuesa, D., Ferra, S., Terrón, A., SanJoaquín, I., Payeras, A., Martínez, O. J., López-Ruz, M. Á., Omar, M., de la Torre-Lima, J., López-Lirola, A., Palomares, J., Blanco, J. R., Montero, M., & García-Vallecillos, C.
(2022). DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks). Viruses, 14(3), 524.
https://doi.org/10.3390/v14030524
